-
2022 in review: Drug development milestones for tropical diseases After a pivot to studying Covid-19, several late-stage tropical disease projects picked the momentum back up in 2022.
Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. Spearheaded by collaborations between non-profit groups and pharma players, new treatments are edging closer to late-stage trials in malaria and neglected tropical diseases such as sleeping sickness.
넶13 2022-12-30
-
API enters partnership to develop antivirals for SARS-CoV-2 variants A high-throughput drug screening platform will be developed to detect new therapies, as well as drug targets under the alliance.
Applied Pharmaceutical Innovation (API) has entered a collaboration with the University of Saskatchewan, Canada, for the discovery and development of new antivirals against emerging variants of the SARS-CoV-2 virus.
넶29 2022-12-30
-
China NMPA accepts Juventas’ NDA for leukaemia treatment
The China National Medical Products Administration (NMPA) has accepted CASI Pharmaceuticals’ partner Juventas Cell Therapy’s new drug application (NDA) of CNCT19 (Inaticabtagene Autoleucel) to treat relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) in adults.
넶18 2022-12-30
-
Conjugated Estrogens (Premarin): Drug Whys
Of great interest to EMS are numerous studies, many demonstrating remarkable outcomes using intravenous doses of conjugated estrogens during resuscitation
넶21 2022-12-30
